WestEnd Advisors’s West Pharmaceutical WST Stock Holding History

WestEnd Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08K	Hold	3	–	–	﹤0.01%	272
2026 Q1	$752	Hold	3	–	–	﹤0.01%	276
2025 Q4	$825	Buy	3 +1	+50%	+$274	﹤0.01%	260
2025 Q3	$525	Sell	2 -1	-33%	-$243	﹤0.01%	308
2025 Q2	$656	Hold	3	–	–	﹤0.01%	249
2025 Q1	$672	Buy	3 +2	+200%	+$551	﹤0.01%	247
2024 Q4	$328	Hold	1	–	–	﹤0.01%	216
2024 Q3	$300	Hold	1	–	–	﹤0.01%	242
2024 Q2	$329	Hold	1	–	–	﹤0.01%	197
2024 Q1	$396	Hold	1	–	–	﹤0.01%	173
2023 Q4	$352	Hold	1	–	–	﹤0.01%	186
2023 Q3	$375	Buy	+1	New	+$387	﹤0.01%	177
2023 Q1	–	Sell	-1	Closed	-$292	–	182
2022 Q4	$235	Hold	1	–	–	﹤0.01%	212
2022 Q3	$0	Hold	1	–	–	﹤0.01%	336
2022 Q2	$302	Buy	+1	New	+$325	﹤0.01%	172
2022 Q1	–	Sell	-1	Closed	-$391	–	165
2021 Q4	$469	Buy	+1	New	+$430	﹤0.01%	160
2021 Q3	–	Hold	0	–	–	–	160
2021 Q2	–	Hold	0	–	–	–	179

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

WestEnd Advisors's WST Position: Q2 2026 in Review

WestEnd Advisors held its West Pharmaceutical (WST) position steady in Q2 2026 at 3 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #272.

WestEnd Advisors first reported a position in WST in Q4 2021 and has held it in 16 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

WestEnd Advisors held 3 shares of West Pharmaceutical worth $1.08K as of Q2 2026.
WestEnd Advisors left its West Pharmaceutical share count unchanged in Q2 2026.
West Pharmaceutical made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #272 holding.
WestEnd Advisors first reported a position in West Pharmaceutical in Q4 2021 and has held it in 16 quarters since.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.